Navigation Links
Viral Genetics Creates Subsidiary to Develop Cancer Therapy
Date:8/7/2009

drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the Company) to license technology developed by M. Karen Newell, Ph. D., that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
2. Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
3. New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
4. BIO Visitors Bring Viral Preparedness to Atlanta
5. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
6. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
7. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
8. Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
9. Researchers decode viral process that prepares cells for HIV infection
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bed bug cases tend to increase during summer. And ... risk of becoming the pests' next victim throughout the season, ... the guide, the company enumerated the steps of getting ... , According to My Cleaning Products, there are two ... during summer: the warm weather and the rise in travel. ...
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... EDT , EAST BRUNSWICK, N.J., May 6 Savient Pharmaceuticals, ... the three months ended March 31, 2009. For the first ... million, or $0.41 per basic and diluted share, on total revenues ... or $0.33 per basic and diluted share on total revenues of ...
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... loss for the quarter ended March 31, 2009 was $31.8 ... $40.7 million or $0.44 per share in the first quarter ... efficiencies as compared to a year ago. Total operating costs ...
... U.S. President Bill Clinton will,participate as one of the main ... 1 and 3 in Sao Paulo, Brazil. The event is ... of the most,important gatherings focused on biofuels in the world. ... Democratic president awarded a second term,in six decades. After leaving ...
Cached Biology Technology:Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 9Nektar Therapeutics Reports First Quarter 2009 Financial Results 2Nektar Therapeutics Reports First Quarter 2009 Financial Results 3Nektar Therapeutics Reports First Quarter 2009 Financial Results 4Nektar Therapeutics Reports First Quarter 2009 Financial Results 5Nektar Therapeutics Reports First Quarter 2009 Financial Results 6Nektar Therapeutics Reports First Quarter 2009 Financial Results 7Nektar Therapeutics Reports First Quarter 2009 Financial Results 8Nektar Therapeutics Reports First Quarter 2009 Financial Results 9President Bill Clinton to Speak at the Ethanol Summit in Brazil 2
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
(Date:5/23/2013)... the team reveal the interplay of brain chemicals which ... Wellcome Trust and BBSRC. , By changing the ... perceptual abilities. While these changes can affect the strength ... fidelity of that response. , Lead author ... communicate with others, you can make yourself better heard ...
(Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Detecting mirror molecules 2Detecting mirror molecules 3
... discovered how the toxoplasmosis parasite may trigger the development ... from the University of Leeds, Faculty of Biological Sciences ... role in the development of these disorders by affecting ... messages in the brain controlling aspects of movement, cognition ...
... University Life Sciences researchers have discovered a new mechanism ... cells, which could lead to the development of a ... is transmitted to humans through bites from mosquitoes. According ... 350 million and 500 million cases of malaria occur ...
... Strosberg of Scripps Florida, was published on March 4, 2009, ... edition, Papers in Press. In the new study, ... more amino acids) derived from the core protein of hepatitis ... dimerization of the core protein (the joining of two identical ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2Researchers identify new way the malaria parasite and red blood cells interact 2Scripps research team identifies key molecules that inhibit viral production 2Scripps research team identifies key molecules that inhibit viral production 3
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Biology Products: